Anti-angiotensin II type 1 receptor autoantibodies (AT1R-AAs) in patients with systemic sclerosis: lack of association with disease manifestations
Angiotensin II type 1 receptor autoantibodies (AT 1 R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney transplantation. They were also suspected to have pathogenetic role in vasculopathic changes in systemic sclerosis (SSc). Clinical data re...
Saved in:
Published in | Rheumatology international Vol. 37; no. 4; pp. 593 - 598 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.04.2017
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Angiotensin II type 1 receptor autoantibodies (AT
1
R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney transplantation. They were also suspected to have pathogenetic role in vasculopathic changes in systemic sclerosis (SSc). Clinical data regarding AT
1
R-AAs in SSc are scarce. In this work, we will examine the relationship between serum levels of AT
1
R-AAs and disease manifestations. Serum samples from SSc patients and healthy controls were analyzed for AT
1
R-AAs by using a commercial ELISA kit. We examined the association of serum levels of AT
1
R-AA with disease duration, systolic pulmonary artery pressure (sPAP) measurements, and disease manifestations like cutaneous, lung and esophageal involvements, and the presence of digital ulcers in a cross-sectional manner. There was no statistically significant difference in levels of AT
1
R-AAs between SSc (
n
= 93) patients and healthy controls (
n
= 66) (
p
= 0.23). Serum levels of AT
1
R-AAs were not correlated with disease duration, sPAP measurements, and showed no association with disease manifestations like lung involvement, esophageal involvement, digital ulcers, and cutaneous fibrosis. In our SSc cohort, AT
1
R-AA serum levels were not different from healthy subjects and higher levels were not associated with any disease manifestation neither. |
---|---|
AbstractList | Angiotensin II type 1 receptor autoantibodies (AT1R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney transplantation. They were also suspected to have pathogenetic role in vasculopathic changes in systemic sclerosis (SSc). Clinical data regarding AT1R-AAs in SSc are scarce. In this work, we will examine the relationship between serum levels of AT1R-AAs and disease manifestations. Serum samples from SSc patients and healthy controls were analyzed for AT1R-AAs by using a commercial ELISA kit. We examined the association of serum levels of AT1R-AA with disease duration, systolic pulmonary artery pressure (sPAP) measurements, and disease manifestations like cutaneous, lung and esophageal involvements, and the presence of digital ulcers in a cross-sectional manner. There was no statistically significant difference in levels of AT1R-AAs between SSc (n = 93) patients and healthy controls (n = 66) (p = 0.23). Serum levels of AT1R-AAs were not correlated with disease duration, sPAP measurements, and showed no association with disease manifestations like lung involvement, esophageal involvement, digital ulcers, and cutaneous fibrosis. In our SSc cohort, AT1R-AA serum levels were not different from healthy subjects and higher levels were not associated with any disease manifestation neither.Angiotensin II type 1 receptor autoantibodies (AT1R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney transplantation. They were also suspected to have pathogenetic role in vasculopathic changes in systemic sclerosis (SSc). Clinical data regarding AT1R-AAs in SSc are scarce. In this work, we will examine the relationship between serum levels of AT1R-AAs and disease manifestations. Serum samples from SSc patients and healthy controls were analyzed for AT1R-AAs by using a commercial ELISA kit. We examined the association of serum levels of AT1R-AA with disease duration, systolic pulmonary artery pressure (sPAP) measurements, and disease manifestations like cutaneous, lung and esophageal involvements, and the presence of digital ulcers in a cross-sectional manner. There was no statistically significant difference in levels of AT1R-AAs between SSc (n = 93) patients and healthy controls (n = 66) (p = 0.23). Serum levels of AT1R-AAs were not correlated with disease duration, sPAP measurements, and showed no association with disease manifestations like lung involvement, esophageal involvement, digital ulcers, and cutaneous fibrosis. In our SSc cohort, AT1R-AA serum levels were not different from healthy subjects and higher levels were not associated with any disease manifestation neither. Angiotensin II type 1 receptor autoantibodies (AT 1 R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney transplantation. They were also suspected to have pathogenetic role in vasculopathic changes in systemic sclerosis (SSc). Clinical data regarding AT 1 R-AAs in SSc are scarce. In this work, we will examine the relationship between serum levels of AT 1 R-AAs and disease manifestations. Serum samples from SSc patients and healthy controls were analyzed for AT 1 R-AAs by using a commercial ELISA kit. We examined the association of serum levels of AT 1 R-AA with disease duration, systolic pulmonary artery pressure (sPAP) measurements, and disease manifestations like cutaneous, lung and esophageal involvements, and the presence of digital ulcers in a cross-sectional manner. There was no statistically significant difference in levels of AT 1 R-AAs between SSc ( n = 93) patients and healthy controls ( n = 66) ( p = 0.23). Serum levels of AT 1 R-AAs were not correlated with disease duration, sPAP measurements, and showed no association with disease manifestations like lung involvement, esophageal involvement, digital ulcers, and cutaneous fibrosis. In our SSc cohort, AT 1 R-AA serum levels were not different from healthy subjects and higher levels were not associated with any disease manifestation neither. Angiotensin II type 1 receptor autoantibodies (AT R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney transplantation. They were also suspected to have pathogenetic role in vasculopathic changes in systemic sclerosis (SSc). Clinical data regarding AT R-AAs in SSc are scarce. In this work, we will examine the relationship between serum levels of AT R-AAs and disease manifestations. Serum samples from SSc patients and healthy controls were analyzed for AT R-AAs by using a commercial ELISA kit. We examined the association of serum levels of AT R-AA with disease duration, systolic pulmonary artery pressure (sPAP) measurements, and disease manifestations like cutaneous, lung and esophageal involvements, and the presence of digital ulcers in a cross-sectional manner. There was no statistically significant difference in levels of AT R-AAs between SSc (n = 93) patients and healthy controls (n = 66) (p = 0.23). Serum levels of AT R-AAs were not correlated with disease duration, sPAP measurements, and showed no association with disease manifestations like lung involvement, esophageal involvement, digital ulcers, and cutaneous fibrosis. In our SSc cohort, AT R-AA serum levels were not different from healthy subjects and higher levels were not associated with any disease manifestation neither. Angiotensin II type 1 receptor autoantibodies (AT1R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney transplantation. They were also suspected to have pathogenetic role in vasculopathic changes in systemic sclerosis (SSc). Clinical data regarding AT 1R-AAs in SSc are scarce. In this work, we will examine the relationship between serum levels of AT1R-AAs and disease manifestations. Serum samples from SSc patients and healthy controls were analyzed for AT1R-AAs by using a commercial ELISA kit. We examined the association of serum levels of AT1R-AA with disease duration, systolic pulmonary artery pressure (sPAP) measurements, and disease manifestations like cutaneous, lung and esophageal involvements, and the presence of digital ulcers in a cross-sectional manner. There was no statistically significant difference in levels of AT 1R-AAs between SSc (n = 93) patients and healthy controls (n = 66) (p = 0.23). Serum levels of AT1R-AAs were not correlated with disease duration, sPAP measurements, and showed no association with disease manifestations like lung involvement, esophageal involvement, digital ulcers, and cutaneous fibrosis. In our SSc cohort, AT1R-AA serum levels were not different from healthy subjects and higher levels were not associated with any disease manifestation neither. |
Author | İlgen, Ufuk Düzgün, Nurşen Yayla, Müçteba Enes |
Author_xml | – sequence: 1 givenname: Ufuk orcidid: 0000-0001-6443-6426 surname: İlgen fullname: İlgen, Ufuk email: ufukilgen@gmail.com organization: Department of Internal Medicine, İbn-i Sina Hospital, Ankara University Medical School – sequence: 2 givenname: Müçteba Enes surname: Yayla fullname: Yayla, Müçteba Enes organization: Department of Internal Medicine, İbn-i Sina Hospital, Ankara University Medical School – sequence: 3 givenname: Nurşen surname: Düzgün fullname: Düzgün, Nurşen organization: Department of Rheumatology, Ankara University Medical School |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28004166$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kVFr1TAYhoNM3NnRH-CNBLzZLqpJ2ian3pWh88BAkAnehTT9MjPbpPZLkfM3_MXm2A1koDcJIc_75s33npGTEAMQ8pKzN5wx9RYZE40sGJdFKcumqJ6QDa9KVXDJvp6QDeNKFLu8nJIzxDuWz1KyZ-RU7BiruJQb8qsNyRcm3PqYIKAPdL-n6TAB5XQGC1OKMzVLiiZzXew9ID1vb_jnom3xgmZ-MslDSEh_-vSN4gETjN5StAPMET2-o4Ox32l01CBG6zMewwr3HsEg0NEE7wDTnyt8Tp46MyC8uN-35MuH9zeXH4vrT1f7y_a6sKUSqRC7quK9q13FQXR1I6rSdp1qVN3zXlQdV84a0SjhpOh7AKuYdCVTvHROVs6UW3K--k5z_LHk5_Xo0cIwmABxQc13NZdNJbLxlrx-hN7FZQ45XaZUU0rBZJ2pV_fU0o3Q62n2o5kP-mHaGVArYPNkcAanrV8_nWbjB82ZPvaq11517lUfe9XHAPyR8sH8fxqxajCz4Rbmv0L_U_QbvDy1fg |
CitedBy_id | crossref_primary_10_3389_fimmu_2022_1045523 crossref_primary_10_1016_j_autrev_2018_06_009 crossref_primary_10_1002_art_43099 crossref_primary_10_1097_BOR_0000000000000550 crossref_primary_10_3389_fimmu_2021_786039 crossref_primary_10_1016_j_humimm_2019_04_007 |
Cites_doi | 10.1016/j.transproceed.2014.11.055 10.1111/ajt.12395 10.1097/00004872-200018070-00017 10.1586/eci.11.56 10.1002/art.38098 10.1056/NEJMoa035717 10.1111/tri.12371 10.1016/j.jcf.2014.07.007 10.1136/ard.2010.135772 10.1186/ar4457 10.1097/TP.0b013e3181fd97f1 10.1097/TP.0000000000000182 10.1164/rccm.201403-0442OC 10.1111/nep.12441 10.1097/TP.0000000000000185 10.1016/j.transproceed.2014.09.029 10.1093/ndt/gfv375 10.4049/jimmunol.138.4.1164 |
ContentType | Journal Article |
Copyright | Springer-Verlag Berlin Heidelberg 2016 Rheumatology International is a copyright of Springer, 2017. |
Copyright_xml | – notice: Springer-Verlag Berlin Heidelberg 2016 – notice: Rheumatology International is a copyright of Springer, 2017. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
DOI | 10.1007/s00296-016-3639-4 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest One Academic Middle East (New) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1437-160X |
EndPage | 598 |
ExternalDocumentID | 4321033171 28004166 10_1007_s00296_016_3639_4 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Ankara Tıplılar Vakfı |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 123 199 1N0 1SB 2.D 203 28- 29P 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67Z 6NX 78A 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAS LLZTM M1P M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZGI ZMTXR ZOVNA ~A9 ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7XB 8FK ABRTQ K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 |
ID | FETCH-LOGICAL-c372t-28441df5f41e2b59243cbb7975d1d24b17fca2972f62ddeec706f30713ff64fa3 |
IEDL.DBID | 7X7 |
ISSN | 0172-8172 1437-160X |
IngestDate | Fri Jul 11 03:46:01 EDT 2025 Fri Jul 25 10:28:35 EDT 2025 Wed Feb 19 02:00:17 EST 2025 Thu Apr 24 23:12:06 EDT 2025 Tue Jul 01 03:38:04 EDT 2025 Fri Feb 21 02:39:59 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | R Digital ulceration Pulmonary arterial hypertension AT Angiotensin II type 1 receptor antibodies Systemic sclerosis AT1R |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c372t-28441df5f41e2b59243cbb7975d1d24b17fca2972f62ddeec706f30713ff64fa3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-6443-6426 |
PMID | 28004166 |
PQID | 1879362065 |
PQPubID | 326313 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_1851694224 proquest_journals_1879362065 pubmed_primary_28004166 crossref_citationtrail_10_1007_s00296_016_3639_4 crossref_primary_10_1007_s00296_016_3639_4 springer_journals_10_1007_s00296_016_3639_4 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20170400 2017-4-00 2017-Apr 20170401 |
PublicationDateYYYYMMDD | 2017-04-01 |
PublicationDate_xml | – month: 4 year: 2017 text: 20170400 |
PublicationDecade | 2010 |
PublicationPlace | Berlin/Heidelberg |
PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
PublicationSubtitle | Clinical and Experimental Investigations |
PublicationTitle | Rheumatology international |
PublicationTitleAbbrev | Rheumatol Int |
PublicationTitleAlternate | Rheumatol Int |
PublicationYear | 2017 |
Publisher | Springer Berlin Heidelberg Springer Nature B.V |
Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
References | Couraud (CR1) 1987; 138 Ohe, Uchida, Yoshizawa, Hirao, Taniguchi, Maruya, Yurugi, Hishida, Maekawa, Uemoto (CR12) 2014; 98 LeRoy, Black, Fleischmajer, Jablonska, Krieg, Medsger, Rowell, Wollheim (CR19) 1988; 15 Budding, van de Graaf, Hoefnagel, Kwakkel-van Erp, van Kessel, Dragun, Hack, Otten (CR14) 2015; 14 Chiron, Bouaziz, Carmagnat, Peffault de Latour, Lafaurie-Bergeron, Robin, Xhaard, Toubert, Charron, Guigue (CR13) 2014; 98 Dragun, Muller, Brasen, Fritsche, Nieminen-Kelha, Dechend, Kintscher, Rudolph, Hoebeke, Eckert (CR4) 2005; 352 Fuss, Hope, Deayton, Bennett, Holdsworth, Carroll, Coates (CR7) 2015; 20 Banasik, Boratynska, Koscielska-Kasprzak, Kaminska, Bartoszek, Zabinska, Myszka, Zmonarski, Protasiewicz, Nowakowska (CR5) 2014; 27 Taniguchi, Rebellato, Cai, Hopfield, Briley, Haisch, Catrou, Bolin, Parker, Kendrick (CR10) 2013; 13 Reinsmoen, Lai, Heidecke, Haas, Cao, Ong, Naim, Wang, Mirocha, Kahwaji (CR11) 2010; 90 Becker, Kill, Kutsche, Guenther, Rose, Tabeling, Witzenrath, Kuhl, Heidecke, Ghofrani (CR15) 2014; 190 Fu, Herlitz, Schulze, Wallukat, Micke, Eftekhari, Sjogren, Hjalmarson, Muller-Esterl, Hoebeke (CR2) 2000; 18 van den Hoogen, Khanna, Fransen, Johnson, Baron, Tyndall, Matucci-Cerinic, Naden, Medsger (CR18) 2013; 65 Xia, Kellems (CR3) 2011; 7 Lee, Park, Kim, Lee, Kim, Kim, Huh (CR9) 2015; 47 Kill, Tabeling, Undeutsch, Kuhl, Gunther, Radic, Becker, Heidecke, Worm, Witzenrath (CR17) 2014; 16 Banasik, Boratynska, Koscielska-Kasprzak, Kaminska, Zmonarski, Mazanowska, Krajewska, Bartoszek, Zabinska, Myszka (CR6) 2014; 46 Lee, Huh, Park, Park, Yang, Jeong, Lee, Park, Cho, Lee (CR8) 2015 Riemekasten, Philippe, Nather, Slowinski, Muller, Heidecke, Matucci-Cerinic, Czirjak, Lukitsch, Becker (CR16) 2011; 70 H Ohe (3639_CR12) 2014; 98 M Taniguchi (3639_CR10) 2013; 13 NL Reinsmoen (3639_CR11) 2010; 90 Y Xia (3639_CR3) 2011; 7 EC LeRoy (3639_CR19) 1988; 15 M Banasik (3639_CR6) 2014; 46 F Hoogen van den (3639_CR18) 2013; 65 A Chiron (3639_CR13) 2014; 98 D Dragun (3639_CR4) 2005; 352 J Lee (3639_CR8) 2015 G Riemekasten (3639_CR16) 2011; 70 M Banasik (3639_CR5) 2014; 27 J Lee (3639_CR9) 2015; 47 A Kill (3639_CR17) 2014; 16 ML Fu (3639_CR2) 2000; 18 A Fuss (3639_CR7) 2015; 20 MO Becker (3639_CR15) 2014; 190 PO Couraud (3639_CR1) 1987; 138 K Budding (3639_CR14) 2015; 14 23941128 - Am J Transplant. 2013 Oct;13(10):2577-89 21895478 - Expert Rev Clin Immunol. 2011 Sep;7(5):659-74 24873781 - Transplantation. 2014 Aug 27;98(4):470-4 26546592 - Nephrol Dial Transplant. 2017 Jul 1;32(7):1244-1250 24472528 - Arthritis Res Ther. 2014 Jan 28;16(1):R29 15703421 - N Engl J Med. 2005 Feb 10;352(6):558-69 24909812 - Transpl Int. 2014 Oct;27(10):1029-38 24122180 - Arthritis Rheum. 2013 Nov;65(11):2737-47 2433343 - J Immunol. 1987 Feb 15;138(4):1164-8 25891704 - Transplant Proc. 2015 Apr;47(3):649-52 10930193 - J Hypertens. 2000 Jul;18(7):945-53 25096855 - J Cyst Fibros. 2015 Jan;14(1):42-5 25726938 - Nephrology (Carlton). 2015 Jul;20(7):467-73 21030904 - Transplantation. 2010 Dec 27;90(12):1473-7 25181620 - Am J Respir Crit Care Med. 2014 Oct 1;190(7):808-17 21081526 - Ann Rheum Dis. 2011 Mar;70(3):530-6 3361530 - J Rheumatol. 1988 Feb;15(2):202-5 25380879 - Transplant Proc. 2014 Oct;46(8):2618-21 24914568 - Transplantation. 2014 Nov 27;98(10):1105-11 |
References_xml | – year: 2015 ident: CR8 article-title: The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation publication-title: Nephrol Dial Transpl – volume: 47 start-page: 649 issue: 3 year: 2015 end-page: 652 ident: CR9 article-title: Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation publication-title: Transplant Proc doi: 10.1016/j.transproceed.2014.11.055 – volume: 13 start-page: 2577 issue: 10 year: 2013 end-page: 2589 ident: CR10 article-title: Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies publication-title: Am J Transplant doi: 10.1111/ajt.12395 – volume: 18 start-page: 945 issue: 7 year: 2000 end-page: 953 ident: CR2 article-title: Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension publication-title: J Hypertens doi: 10.1097/00004872-200018070-00017 – volume: 7 start-page: 659 issue: 5 year: 2011 end-page: 674 ident: CR3 article-title: Receptor-activating autoantibodies and disease: preeclampsia and beyond publication-title: Expert Rev Clin Immunol doi: 10.1586/eci.11.56 – volume: 65 start-page: 2737 issue: 11 year: 2013 end-page: 2747 ident: CR18 article-title: 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative publication-title: Arthritis Rheum doi: 10.1002/art.38098 – volume: 352 start-page: 558 issue: 6 year: 2005 end-page: 569 ident: CR4 article-title: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection publication-title: N Engl J Med doi: 10.1056/NEJMoa035717 – volume: 27 start-page: 1029 issue: 10 year: 2014 end-page: 1038 ident: CR5 article-title: The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes publication-title: Transpl Int doi: 10.1111/tri.12371 – volume: 14 start-page: 42 issue: 1 year: 2015 end-page: 45 ident: CR14 article-title: Anti-ETAR and anti-AT1R autoantibodies are elevated in patients with endstage cystic fibrosis publication-title: J Cyst Fibros doi: 10.1016/j.jcf.2014.07.007 – volume: 70 start-page: 530 issue: 3 year: 2011 end-page: 536 ident: CR16 article-title: Involvement of functional autoantibodies against vascular receptors in systemic sclerosis publication-title: Ann Rheum Dis doi: 10.1136/ard.2010.135772 – volume: 16 start-page: R29 issue: 1 year: 2014 ident: CR17 article-title: Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis publication-title: Arthritis Res Ther doi: 10.1186/ar4457 – volume: 138 start-page: 1164 issue: 4 year: 1987 end-page: 1168 ident: CR1 article-title: Anti-angiotensin II anti-idiotypic antibodies bind to angiotensin II receptor publication-title: J Immunol – volume: 90 start-page: 1473 issue: 12 year: 2010 end-page: 1477 ident: CR11 article-title: Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients publication-title: Transplantation doi: 10.1097/TP.0b013e3181fd97f1 – volume: 98 start-page: 470 issue: 4 year: 2014 end-page: 474 ident: CR13 article-title: Anti-Angiotensin type 1 receptor antibodies in chronic graft-versus-host disease publication-title: Transplantation doi: 10.1097/TP.0000000000000182 – volume: 15 start-page: 202 issue: 2 year: 1988 end-page: 205 ident: CR19 article-title: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis publication-title: J Rheumatol – volume: 190 start-page: 808 issue: 7 year: 2014 end-page: 817 ident: CR15 article-title: Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201403-0442OC – volume: 20 start-page: 467 issue: 7 year: 2015 end-page: 473 ident: CR7 article-title: C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies publication-title: Nephrol (Carlton) doi: 10.1111/nep.12441 – volume: 98 start-page: 1105 issue: 10 year: 2014 end-page: 1111 ident: CR12 article-title: Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal publication-title: Transplantation doi: 10.1097/TP.0000000000000185 – volume: 46 start-page: 2618 issue: 8 year: 2014 end-page: 2621 ident: CR6 article-title: Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss publication-title: Transplant Proc doi: 10.1016/j.transproceed.2014.09.029 – volume: 20 start-page: 467 issue: 7 year: 2015 ident: 3639_CR7 publication-title: Nephrol (Carlton) doi: 10.1111/nep.12441 – volume: 98 start-page: 1105 issue: 10 year: 2014 ident: 3639_CR12 publication-title: Transplantation doi: 10.1097/TP.0000000000000185 – volume: 47 start-page: 649 issue: 3 year: 2015 ident: 3639_CR9 publication-title: Transplant Proc doi: 10.1016/j.transproceed.2014.11.055 – volume: 14 start-page: 42 issue: 1 year: 2015 ident: 3639_CR14 publication-title: J Cyst Fibros doi: 10.1016/j.jcf.2014.07.007 – volume: 16 start-page: R29 issue: 1 year: 2014 ident: 3639_CR17 publication-title: Arthritis Res Ther doi: 10.1186/ar4457 – volume: 65 start-page: 2737 issue: 11 year: 2013 ident: 3639_CR18 publication-title: Arthritis Rheum doi: 10.1002/art.38098 – volume: 90 start-page: 1473 issue: 12 year: 2010 ident: 3639_CR11 publication-title: Transplantation doi: 10.1097/TP.0b013e3181fd97f1 – volume: 27 start-page: 1029 issue: 10 year: 2014 ident: 3639_CR5 publication-title: Transpl Int doi: 10.1111/tri.12371 – volume: 46 start-page: 2618 issue: 8 year: 2014 ident: 3639_CR6 publication-title: Transplant Proc doi: 10.1016/j.transproceed.2014.09.029 – volume: 352 start-page: 558 issue: 6 year: 2005 ident: 3639_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa035717 – year: 2015 ident: 3639_CR8 publication-title: Nephrol Dial Transpl doi: 10.1093/ndt/gfv375 – volume: 13 start-page: 2577 issue: 10 year: 2013 ident: 3639_CR10 publication-title: Am J Transplant doi: 10.1111/ajt.12395 – volume: 98 start-page: 470 issue: 4 year: 2014 ident: 3639_CR13 publication-title: Transplantation doi: 10.1097/TP.0000000000000182 – volume: 15 start-page: 202 issue: 2 year: 1988 ident: 3639_CR19 publication-title: J Rheumatol – volume: 138 start-page: 1164 issue: 4 year: 1987 ident: 3639_CR1 publication-title: J Immunol doi: 10.4049/jimmunol.138.4.1164 – volume: 7 start-page: 659 issue: 5 year: 2011 ident: 3639_CR3 publication-title: Expert Rev Clin Immunol doi: 10.1586/eci.11.56 – volume: 190 start-page: 808 issue: 7 year: 2014 ident: 3639_CR15 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201403-0442OC – volume: 70 start-page: 530 issue: 3 year: 2011 ident: 3639_CR16 publication-title: Ann Rheum Dis doi: 10.1136/ard.2010.135772 – volume: 18 start-page: 945 issue: 7 year: 2000 ident: 3639_CR2 publication-title: J Hypertens doi: 10.1097/00004872-200018070-00017 – reference: 24472528 - Arthritis Res Ther. 2014 Jan 28;16(1):R29 – reference: 21030904 - Transplantation. 2010 Dec 27;90(12):1473-7 – reference: 24909812 - Transpl Int. 2014 Oct;27(10):1029-38 – reference: 23941128 - Am J Transplant. 2013 Oct;13(10):2577-89 – reference: 26546592 - Nephrol Dial Transplant. 2017 Jul 1;32(7):1244-1250 – reference: 25891704 - Transplant Proc. 2015 Apr;47(3):649-52 – reference: 25380879 - Transplant Proc. 2014 Oct;46(8):2618-21 – reference: 10930193 - J Hypertens. 2000 Jul;18(7):945-53 – reference: 24873781 - Transplantation. 2014 Aug 27;98(4):470-4 – reference: 3361530 - J Rheumatol. 1988 Feb;15(2):202-5 – reference: 2433343 - J Immunol. 1987 Feb 15;138(4):1164-8 – reference: 25726938 - Nephrology (Carlton). 2015 Jul;20(7):467-73 – reference: 21081526 - Ann Rheum Dis. 2011 Mar;70(3):530-6 – reference: 25181620 - Am J Respir Crit Care Med. 2014 Oct 1;190(7):808-17 – reference: 24914568 - Transplantation. 2014 Nov 27;98(10):1105-11 – reference: 15703421 - N Engl J Med. 2005 Feb 10;352(6):558-69 – reference: 24122180 - Arthritis Rheum. 2013 Nov;65(11):2737-47 – reference: 25096855 - J Cyst Fibros. 2015 Jan;14(1):42-5 – reference: 21895478 - Expert Rev Clin Immunol. 2011 Sep;7(5):659-74 |
SSID | ssj0017660 |
Score | 2.1605663 |
Snippet | Angiotensin II type 1 receptor autoantibodies (AT
1
R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in... Angiotensin II type 1 receptor autoantibodies (AT R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney... Angiotensin II type 1 receptor autoantibodies (AT1R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney... |
SourceID | proquest pubmed crossref springer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 593 |
SubjectTerms | Adult Aged Autoantibodies - blood Biomarkers Cross-Sectional Studies Female Humans Male Medicine Medicine & Public Health Middle Aged Receptor, Angiotensin, Type 1 - immunology Rheumatology Scleroderma, Systemic - blood Scleroderma, Systemic - complications Scleroderma, Systemic - diagnosis Scleroderma, Systemic - immunology Severity of Illness Index Skin Ulcer - blood Skin Ulcer - etiology Skin Ulcer - immunology |
SummonAdditionalLinks | – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fa9cwED_mBPFF1Pmj25QIPkwl0KZp2u6tiGMbzAfZF_ZW0jQnBWmH7fcf2V-8u_7SMRV86UuvScldks_lc3cBeB_aPLY6Q-kzp6UmxcoMyZbRxZ5MoMIk49zhi6_mdKPPr5KrOY-7X6LdF0pyXKnXZDcmkNj7NTI2TF8-gIcJue4cx7VRxUodpGZMDWbfRmb0WKjMPzVxdzO6hzDvsaPjpnPyFJ7MaFEUk3qfwY5vn8Oji5kP34Oboh0aadvvTTdGorfi7EzwqaqIBC1l_po8amG3Q0fj11QdRwyKo-Iy-iaLov8gSH6uq9oLPpAVU13nxomeuqNfbvpjwSd8okNhfylyEp65HcEVNND3E6ffv4DNyZfLz6dyvmVBujhVg6T9SUc1Jqgjr6qE_LHYVVWap0kd1UpXUYrOqjxVaBSthd6locGYnVtEo9HGL2G37Vr_GkSukfAXhpjrWsfWWoJXlQtVnSeEWiIXQLgMd-nmEuR8E8aPci2ePGqo5LAz1lCpA_i4fnI91d_4l_DhosNynop9ydep0y5NUCuAd-trmkTMjNjWd1uWYbpQE5wJ4NWk-7U3lXFNMmMC-LQYw2-N_-1X9v9L-gAeK4YLY0TQIewOP7f-DYGdoXo7GvctFmj1oQ priority: 102 providerName: Springer Nature |
Title | Anti-angiotensin II type 1 receptor autoantibodies (AT1R-AAs) in patients with systemic sclerosis: lack of association with disease manifestations |
URI | https://link.springer.com/article/10.1007/s00296-016-3639-4 https://www.ncbi.nlm.nih.gov/pubmed/28004166 https://www.proquest.com/docview/1879362065 https://www.proquest.com/docview/1851694224 |
Volume | 37 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9VAEF60BfFFrLdG27KCD15YTDabmy8Sy6mt0iKlB44vDbubXQlIcnRz_os_15lkk1qKfUkg2SRLZjIzO9_kG0JehbKIpcgtM7kWTIBgWW5Bl62ODaiAskmO_w6fnqXHS_Fllax8ws35ssrJJg6Guu405sjfY1dsMLbgMT-ufzHsGoXoqm-hcZdsI3UZanW2mhdcyH045FjASbMcNhOqGQ4kohzLb6OUxSmCodf90o1g8wZQOvifo4fkgQ8caTlKeofcMe0jcu_UQ-OPyZ-y7Rsm2x9NNxSlt_TkhGKClUYUrJpZw-Kayk3fwatsVIfFg_R1eXHpNopGl-esLN0bCld5olVHMUNLR6LnRlMHD4WJN-4DxZQf7SyVV5IdB3uwhyKlhjVuBPndE7I8WlwcHjPfdoHpOOM9A4clotomVkSGqwQWaLFWKiuypI5qLlSUWS15kXGbcjCORmdhamNc7VqbCivjp2Sr7VqzS2ghLARkNrSFqEUspYR4S-mQ10UCYUykAxJOL73SnpMcW2P8rGY25UFOFdahoZwqEZC38yXrkZDjtsF7kyQr_2266kqTAvJyPg1fFUIlsjXdBscgfiggvgnIs1ED5qfxHEnK0jQg7yaV-Ofm_5vK89un8oLc5xgwDDVBe2Sr_70x-xDu9Opg0OkDsl1-_v51AftPi7Nv53B0ycu_CHL_YQ |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9VAEB5qBe2LeG-06goKXlhMNpubIBLUco7t6YOcwnlq3Gx2JSDJ0eQg_hN_hb_RmdyqFPvWl7xkN1ky385-c8kMwBNXJb6SseUm1pJLFCyPLWLZat8gBHIbxPTv8OIonB3Lj6tgtQW_x39hKK1y1Imdoi5qTT7yV9QVG5Utnphv1984dY2i6OrYQqOHxYH5-QNNtubN_D3K96kQ-x-W72Z86CrAtR-JlqM-ll5hAys9I_IA7Q9f53mUREHhFULmXmS1EkkkbChw7xsduaH1yZizNpRW-fjcS3AZD16XjL1oNRl4VGux8-kgKeAxXsYoqtsVLRWU7uuF3A8p-PrvOXiG3J4JzHbn3f51uDYQVZb2yLoBW6a6CVcWQyj-FvxKq7bkqvpS1l0SfMXmc0YOXeYx1KJmjcY8U5u2RtGVeU3JiuxZujxpNjnzTj7xNG2eM5w1FHZtGHmEWV9YutSswZfiwsvmNSMXI6stU6dI6gcPwSVGJTysafqkguY2HF-IQO7AdlVXZhdYIi0SQOvaRBbSV0ohv8u1K4okQNrkaQfc8aNneqiBTq04vmZT9eZOThnlvZGcMunAi2nKui8Act7gvVGS2aALmuwUuQ48nm7jLqbQjKpMvaExFK-UyKccuNsjYHqbiKkoWhg68HKExF8P_99S7p2_lEdwdbZcHGaH86OD-7AjiKx0-Uh7sN1-35gHSLXa_GGHbwafL3pD_QHZMDhe |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9VAEB7qKRRfxLvRqisoeGFpstncBJFoe-ix9lBKC31qutnsSkCSo8lB_Cf-Fn-dM7mcKsW-9SUv2d0smW9nZ_abnQF47qrEVzK23MRacomC5bFFLFvtG4RAboOY7g7vz8PdY_npJDhZg9_jXRgKqxx1Yqeoi1rTGfkWVcVGZYs75pYdwiIOtqfvF984VZAipnUsp9FDZM_8_IHuW_Nuto2yfiHEdOfo4y4fKgxw7Uei5aibpVfYwErPiDxAX8TXeR4lUVB4hZC5F1mtRBIJGwrUA0ZHbmh9cuysDaVVPo57DdYj8oomsP5hZ35wuOIworC7o0xOFo_xMXKqbpfCVFDwrxdyPyQq9t9d8YKpe4Gm7Xa_6U24MZitLO1xdgvWTHUbNvYHYv4O_EqrtuSq-lLWXUh8xWYzRse7zGOoU80CXXumlm2NgizzmkIX2cv06LRZ5sw7PeRp2rxi2GtI89owOh9mfZrpUrMGP4oTL5u3jA4cWW2ZOsdV33igmhgl9LCm6UMMmrtwfCUiuQeTqq7MA2CJtGgOWtcmspC-UgqtvVy7okgCNKI87YA7_vRMDxnRqTDH12yVy7mTU0ZRcCSnTDrwetVl0acDuazx5ijJbNAMTXaOYweerV7jmiaiRlWmXlIbYi8lWlcO3O8RsPqaiClFWhg68GaExF-D_28qDy-fylPYwMWUfZ7N9x7BdUGWSxectAmT9vvSPEa7q82fDABncHbVa-oP4KI9-Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Anti-angiotensin+II+type+1+receptor+autoantibodies+%28AT%5Esub+1%5ER-AAs%29+in+patients+with+systemic+sclerosis%3A+lack+of+association+with+disease+manifestations&rft.jtitle=Rheumatology+international&rft.au=Ilgen%2C+Ufuk&rft.au=Yayla%2C+M%C3%BC%C3%A7teba+Enes&rft.au=D%C3%BCzg%C3%BCn%2C+Nursen&rft.date=2017-04-01&rft.pub=Springer+Nature+B.V&rft.issn=0172-8172&rft.eissn=1437-160X&rft.volume=37&rft.issue=4&rft.spage=593&rft_id=info:doi/10.1007%2Fs00296-016-3639-4&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=4321033171 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0172-8172&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0172-8172&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0172-8172&client=summon |